Definitive Contract HHSN261201300065C

<p>This is a $299,990.00 firm-fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Evorx Technologies, Inc., a small disadvantaged business. The contract was set aside for small businesses. The award is for an unspecified product or service related to the NCI's mission, with a period of performance ending on February 28, 2017. No additional details about the specific requirements or work to be performed are provided.</p>

This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Imaginab, Inc. The contract, valued at $224,264, is for the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract has a firm fixed-price pricing type and a completion date of September 29, 2012.</p>

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

<p>This is a $249,330.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to ITI Health, Inc. (doing business as Zielbio) for a Small Business Innovation Research (SBIR) Phase I project on novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract was awarded on September 30, 2011 with a completion date of December 5, 2013. This award is designated as a Total Small Business set-aside contract.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

<p>This is a Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Caerus Discovery, LLC, a Woman-Owned Small Business. The contract is valued at $224,475.00 and has a completion date of June 11, 2015. The contract is for the delivery of a monoclonal antibody targeting cancer stem cells. No set-aside was used for this award. The place of performance is Nokesville, Virginia.</p>

<p>This is a $191,326 firm-fixed-price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lipomedics LTD, a small business limited liability company, to reformulate cancer therapeutics using nanotechnology. The contract has a ceiling value of $191,326 and an ultimate completion date of November 1, 2013. This contract is set aside for total small business participation.</p>

<p>The National Cancer Institute awarded a $999,685 definitive contract to A&amp;G Pharmaceutical, Inc. for smart fusion high affinity peptide capture reagents on September 22, 2015, under cost plus fixed fee pricing with no set-aside.</p> <p>Place of performance is Columbia, MD. The contract ceiling value is $999,685 with an ultimate completion date of March 31, 2018.</p>

This is a $247,568 Firm Fixed Price contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for research and development related to a novel PET imaging agent, [18F]F-ARAG, to assess response to cancer immunotherapies. This contract is part of NCI's Small Business Innovation Research (SBIR) program, which sets aside certain research and development contracts for small businesses. Cellsight Technologies has also...